I work at the interfaces of biologics manufacturing. Between development and manufacturing, data science and manufacturing science. Today that work is mostly about AI. Getting the data ready is the way in, and agentic AI is finally making it real.
Nearly thirty years of biologics CMC work have taught me that manufacturing excellence comes down to how well we monitor, understand, and control process variability. At Sanofi and Genzyme I have led manufacturing science organizations of up to 50 people, responsible for scale-up, technology transfer, continued process verification, cGMP production support, and critical manufacturing investigations. A decade of that was on the front line in a cGMP plant.
I started working with AI on biologics problems at MIT nearly forty years ago. My doctorate used nonlinear data reconciliation for troubleshooting. Since then I have followed these methods, assessed them, and looked for the right place to apply them. For most of that time the data was too thin and the wrangling too onerous. Agentic AI is finally changing both.
My current role is Head of MSAT Process Monitoring and Data Science/AI Strategy at Sanofi, working across a global biologics network. Three Sanofi Global Innovation Awards came along the way. Board service includes the PDA Science Advisory Board, as an AI expert, the MIT Leaders for Global Operations Governing Board, and the organizing committee of AIChE's PD2M conference. My Sc.D. in chemical engineering is from MIT. My B.S. is from the University of Connecticut, where honors included being named Big East Scholar-Athlete of the Year and later induction into the Academy of Distinguished Engineers.
Process Monitoring AI Projects
Two open efforts I am building to move process monitoring toward AI: one to measure whether the data is ready, the other to test the AI before it touches real data.
BioMetre
A framework that scores how ready an organization's data is for AI, turning a vague question into a number you can track and improve. It anchors the "Are We There Yet?" digital maturity model I present, and I am working to establish it as an industry benchmark.
AI-mAb
An open simulator that generates realistic biologics process data, so AI tools can be developed and stress-tested without waiting on scarce or proprietary datasets. Non-proprietary and available to the field.
Talks and media
"Your talk was super educational. You really are the OG of AI for bioprocess." Richard C. Willson, Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering, University of Houston
Unlocking Smarter Bioprocessing through Better Data Collection, Quality, and Analysis
Panel episode, hosted by Maximilian Krippl, with Andrea Arsiccio, Ayca Cetinkaya, and Mario P. Pereira. Recorded at Bioprocessing Summit Europe, Barcelona. Bioprocessing Unfiltered, August 2026.
▶ Listen to episode ▶ Watch on YouTube
Regulatory Panel on AI Guidance
Panelist, with FDA and MHRA. ISPE AI Life Sciences Summit, Boston, June 2026.
LinkedIn post Event page
Are We There Yet? A Digital Maturity Model for Process Monitoring and AI in Biologics Manufacturing
Day Two keynote. BioTalk US 2026.
LinkedIn post
Process Data Readiness for AI in Biologics Manufacturing
Plenary keynote. Cambridge Healthtech Institute Bioprocessing Summit Europe, Barcelona.
LinkedIn post
Bioprocessing Unfiltered Podcast
With William Whitford. Cambridge Healthtech Institute.
▶ Listen to episode LinkedIn postAre We There Yet?
Recorded plenary talk. Pharma Manufacturing World Summit 2025.
▶ Watch on Vimeo LinkedIn postPDA Week 2026 Interview
Two segments with Richard Jaenisch.
▶ Part 1: The Next Wave of Pharma AI ▶ Part 2: Measuring Data Readiness of AI
The Innovation Imperative: Driving Change with Digital Tools and AI
Panelist, with Mark Hill, Karin Shanahan, and Joseph Horvath. American Pharma Manufacturing and Outsourcing Summit, Boston, November 2025.
LinkedIn postAIChE PD2M Conference
Organizing committee. At PD2M, hosted at Amgen, introduced former intern Jason Kelly, CEO of Ginkgo Bioworks, for his keynote on autonomous labs.
LinkedIn post
Opportunities and Challenges in Biologics Manufacturing Process Data Analytics Innovation
National Academy of Sciences, "Innovations in Pharmaceutical Manufacturing" workshop, Washington DC, February 2020.
An invited talk at a National Academies workshop convened to inform a committee writing a report for FDA on process data analytics technologies expected in biologics manufacturing.
▶ Watch on Vimeo Slides (PDF)Recent LinkedIn Posts
MIT Leaders for Global Operations Class of 2028 visits Sanofi Framingham
Pan-Mass Challenge 2026: 168 miles for Dana-Farber with Team FLAMES
Sleep data, agentic AI, BioMetre concepts
2025 Daniel I.C. Wang Lecture, featuring Chetan Goudar
A grading memo and an MIT classmate: David Y. H. Chang
Introducing a former intern at PD2M: Jason Kelly, CEO of Ginkgo Bioworks
Barcelona plenary keynote recap
PDA Week 2026: is AI ready, and is the data ready?
PDA Science Advisory Board appointment
Personal
Life and work run together. A camera that finds its way into interesting rooms, and a habit of analyzing whatever data life provides.
Thirteen years after running for my niece Brianna, meeting her doctor
Two Nobel laureates at home in one week: medicine and the economics of AI
Covid-19 data, analyzed like process data
Three takeaways from volunteering at Paris 2024
Fig City News, founding director of Newton's community newspaper
Weekend projects testing the limits of agentic coding
Apps built to scratch two itches at once: a real need of my own, and the urge to find out how far agentic coding can take a real iOS app.
Races for causes
Marathons and long rides. Over $57,000 raised so far.